RHOEN-KLINIKUM AG (RHK.DE) Fundamental Analysis & Valuation

FRA:RHK • DE0007042301

Current stock price

12.4 EUR
-0.1 (-0.8%)
Last:

This RHK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. RHK.DE Profitability Analysis

1.1 Basic Checks

  • In the past year RHK was profitable.
  • In the past year RHK had a positive cash flow from operations.
  • RHK had positive earnings in each of the past 5 years.
  • In the past 5 years RHK always reported a positive cash flow from operatings.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • With a Return On Assets value of 2.02%, RHK is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of 2.90%, RHK is doing worse than 68.97% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 2.67%, RHK is doing worse than 68.97% of the companies in the same industry.
  • RHK had an Average Return On Invested Capital over the past 3 years of 2.34%. This is below the industry average of 6.20%.
  • The last Return On Invested Capital (2.67%) for RHK is above the 3 year average (2.34%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROIC 2.67%
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6

1.3 Margins

  • The Profit Margin of RHK (2.28%) is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of RHK has declined.
  • With a Operating Margin value of 2.86%, RHK is not doing good in the industry: 68.97% of the companies in the same industry are doing better.
  • In the last couple of years the Operating Margin of RHK has declined.
  • With a decent Gross Margin value of 66.81%, RHK is doing good in the industry, outperforming 68.97% of the companies in the same industry.
  • RHK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RHK.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RHK is destroying value.
  • Compared to 1 year ago, RHK has about the same amount of shares outstanding.
  • Compared to 5 years ago, RHK has about the same amount of shares outstanding.
  • The debt/assets ratio for RHK has been reduced compared to a year ago.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.04 indicates that RHK is not in any danger for bankruptcy at the moment.
  • RHK has a Altman-Z score of 3.04. This is amongst the best in the industry. RHK outperforms 86.21% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.09, RHK belongs to the best of the industry, outperforming 96.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.04
ROIC/WACC0.41
WACC6.58%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • RHK has a Current Ratio of 2.28. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of RHK (2.28) is better than 96.55% of its industry peers.
  • A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.19, RHK belongs to the best of the industry, outperforming 96.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.19
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RHK.DE Growth Analysis

3.1 Past

  • RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.41%.
  • Measured over the past 5 years, RHK shows a small growth in Earnings Per Share. The EPS has been growing by 0.03% on average per year.
  • The Revenue has grown by 9.10% in the past year. This is quite good.
  • The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%

3.2 Future

  • Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.55% on average per year.
  • The Revenue is expected to grow by 5.92% on average over the next years.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.55%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.92%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

2

4. RHK.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 21.75, RHK is valued on the expensive side.
  • Based on the Price/Earnings ratio, RHK is valued a bit more expensive than the industry average as 62.07% of the companies are valued more cheaply.
  • The average S&P500 Price/Earnings ratio is at 26.91. RHK is around the same levels.
  • A Price/Forward Earnings ratio of 16.23 indicates a correct valuation of RHK.
  • Based on the Price/Forward Earnings ratio, RHK is valued a bit more expensive than 65.52% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.68. RHK is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 21.75
Fwd PE 16.23
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.08
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.06
PEG (5Y)639.72
EPS Next 2Y10.47%
EPS Next 3Y11.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. RHK.DE Dividend Analysis

5.1 Amount

  • RHK has a Yearly Dividend Yield of 1.64%.
  • RHK's Dividend Yield is comparable with the industry average which is at 1.93.
  • Compared to an average S&P500 Dividend Yield of 1.89, RHK has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.64%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 2026 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • 17.78% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RHK.DE Fundamentals: All Metrics, Ratios and Statistics

RHOEN-KLINIKUM AG

FRA:RHK (4/9/2026, 7:00:00 PM)

12.4

-0.1 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-26
Earnings (Next)05-07
Inst Owners0.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap830.30M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (16.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.64%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 21.75
Fwd PE 16.23
P/S 0.5
P/FCF N/A
P/OCF 13.46
P/B 0.64
P/tB 0.74
EV/EBITDA 0.08
EPS(TTM)0.57
EY4.6%
EPS(NY)0.76
Fwd EY6.16%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.43%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.06
PEG (5Y)639.72
Graham Number15.78
Profitability
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROCE 3.25%
ROIC 2.67%
ROICexc 4.45%
ROICexgc 5.55%
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
FCFM N/A
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.07
Cap/Depr 112.99%
Cap/Sales 4.21%
Interest Coverage 14.78
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.19
Altman-Z 3.04
F-Score6
WACC6.58%
ROIC/WACC0.41
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.55%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.92%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y27.95%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%

RHOEN-KLINIKUM AG / RHK.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


How profitable is RHOEN-KLINIKUM AG (RHK.DE) stock?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.


How financially healthy is RHOEN-KLINIKUM AG?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


What is the earnings growth outlook for RHOEN-KLINIKUM AG?

The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 4.3% in the next year.